# A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

Source: https://onco.cc/trials/nct07286149/  
OnCo record `nct07286149` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Calderasib, Patritumab deruxtecan, Sacituzumab tirumotecan and Cetuximab in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) is a phase 1/2 interventional study registered as NCT07286149 by Merck Sharp & Dohme LLC, with 140 participants planned, started 2026-04-30 and due to reach its primary completion in 2029-08-17. Interventions recorded: MK-1084, Patritumab deruxtecan, Sacituzumab tirumotecan, Cetuximab and Rescue Medications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07286149
- Phase: 1/2
- Setting: KEYMAKER-U01 Substudy 01F: A Phase 1b/2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 140

## Sources

- ClinicalTrials.gov NCT07286149: https://clinicaltrials.gov/study/NCT07286149

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Calderasib](https://onco.cc/drugs/calderasib/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [Patritumab deruxtecan](https://onco.cc/drugs/patritumab-deruxtecan/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct07286149.json